CAR-T cell therapy for severe autoimmune rheumatic diseases
Treatments studied
Part of Bones, joints & muscles, Brain & nervous system, Immune system & allergy, Skin clinical trials.
This trial tests a new treatment called CAR-T cell therapy for people with severe autoimmune rheumatic diseases that have not improved with other treatments. The therapy uses your own immune cells, which are modified in a lab to attack the cells causing the disease, potentially reducing symptoms and improving quality of life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with a severe form of one of these conditions: rheumatoid arthritis, lupus, Sjogren's syndrome, systemic sclerosis, or inflammatory myositis.
- You have tried at least two standard treatments (like immunosuppressants or biologics) without success or you could not tolerate them.
- Your kidney function is adequate (creatinine clearance greater than 30 mL/min).
- You are willing to travel to the study site and stay within an hour's drive for the first 30 days after treatment.
- You agree to use effective contraception or abstain from sex for at least 12 months after the infusion.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing whether a type of immune cell therapy called CAR-T cells can help people with severe autoimmune diseases that have not improved with standard treatments. It may offer a new option for conditions like lupus, Sjogren's syndrome, or vasculitis when other therapies have failed.
This trial tests a new CAR-T cell therapy (C-CAR168) for people with several autoimmune diseases that have not responded to standard treatments. It aims to see if this therapy can control the disease when other medicines have failed.
This trial is testing a new type of cell therapy called universal CAR-T cells combined with immunosuppressant drugs for people with hard-to-treat autoimmune diseases. The goal is to see if this approach is safe and can help reduce disease activity.
This study tests a new type of cell therapy called CAR-T cells that target three proteins (CD19, CD22, BCMA) to treat people with autoimmune diseases that have not responded to standard treatments. The goal is to see if it can reset the immune system and reduce disease activity.
This trial tests a new treatment using your own immune cells (called CAR-T cells) designed to target and attack cells that cause autoimmune diseases. It is for people with lupus, Sjögren's syndrome, inflammatory myopathy, scleroderma, Behcet's disease, ANCA-associated vasculitis, IgG4-related disease, antiphospholipid syndrome, or thrombotic thrombocytopenic purpura who have not improved with standard therapies.
This trial tests a new type of CAR-T cell therapy that targets two proteins (CD19 and BCMA) on immune cells, to reset the immune system in people with severe autoimmune diseases like lupus, scleroderma, vasculitis, myositis, or Sjögren's syndrome. It aims to reduce disease activity and potentially improve quality of life.
Hear when a new Systemic Sclerosis (SSc) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.